Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.45 |
| ▸ | KYNU | Q16719 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | GCLC | P48506 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600100 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL1395227 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL21518548 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL44030 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL44031 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL6570277 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL5046067 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| Water SCHEMBL1157748 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL22720617 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11PMP22KYNUNOS2 | |
| SCHEMBL4872178 | 0.97 | PTGS1 (0.44) | PTGS1SLC7A11PMP22KYNUNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | claimed |
| EP-4464715-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTx Limited (GB) | 2024-11-20 | — | — | EP | claimed |
| EP-3359138-B1 | DIETARY SUPPLEMENTATION TO ACHIEVE OXY-REDOX HOMEOSTASIS AND EPIGENETIC STABILITY | PARTHENOGEN SAGL (CH) | 2024-04-24 | — | — | EP | claimed |
| US-11898250-B2 | Formulation for the etching of polymer materials prior to coating of the materials | AVANZARE INNOVACIÓN TECNOLÓGICA, S.L. (ES) | 2024-02-13 | — | — | US | claimed |
| US-20240000957-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2024-01-04 | — | — | US | claimed |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | claimed |
| EP-3917339-B1 | AN ORAL NICOTINE PRODUCT COMPRISING A PH ADJUSTING AGENT | SWEDISH MATCH NORTH EUROPE AB (SE) | 2023-06-07 | — | — | EP | claimed |
| WO-2023007088-A1 | FOOD SUPPLEMENT FOR COMBATING FEMALE AND MALE INFERTILITY | NURIBIOL (FR) | 2023-02-02 | — | — | WO | claimed |
| US-20220095671-A1 | AN ORAL NICOTINE PRODUCT COMPRISING A PH ADJUSTING AGENT | SWEDISH MATCH NORTH EUROPE AB (SE) | 2022-03-31 | — | — | US | claimed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | claimed |
| US-6733651-B1 | Method for producing a cyanide-free solution of a gold compound that is suitable for galvanic gold baths | W. C. HERAEUS GMBH & CO. KG (DE) | 2004-05-11 | — | — | US | claimed |
| US-20030211172-A1 | Composition and method for substantially reducing the deleterious effects of alcohol on the body | JONES JEREMY PARK (US) | 2003-11-13 | — | — | US | claimed |
| EP-1198623-B1 | METHOD FOR PRODUCING A CYANIDE-FREE SOLUTION OF A GOLD COMPOUND THAT IS SUITABLE FOR GALVANIC GOLD BATHS | HERAEUS GMBH W C (DE) | 2003-03-19 | — | — | EP | claimed |
| WO-2002072048-A2 | USE OF DIVALENT TROPOLONE SALTS FOR TREATMENT OF THE HAIR | L'OREAL (FR) | 2002-09-19 | — | — | WO | claimed |
| EP-0957890-B1 | HAIR TREATMENT COMPOSITION CONTAINING METAL-AMINOACID COMPLEX | UNILEVER PLC (GB) | 2002-02-13 | — | — | EP | claimed |
| EP-0626166-B1 | New process for permanent waving of hair and the composition therefor containing in association an amino or amidothiol and at least a mineral bromide | OREAL (FR) | 1997-03-19 | — | — | EP | claimed |
| US-5576326-A | Copper amino acidate diimine nitrate compounds and their methyl derivatives and a process for preparing them | UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (UNAM) (MX) | 1996-11-19 | — | — | US | claimed |
| EP-0626166-A1 | New process for permanent waving of hair and the composition therefore containing in association an amino or amidotial and at least a mineral bromide | L'OREAL (FR) | 1994-11-30 | — | — | EP | claimed |
| EP-0434445-A2 | Process to obtain new mixed copper aminoacidate complexes from phenanthrolines and their alkyl derivatives to be used as anticancerigenic agents | UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (MX) | 1991-06-26 | — | — | EP | claimed |
| EP-0065395-B1 | IMPROVED CHYMOPAPAIN AND METHOD FOR ITS PRODUCTION AND USE | BOOTS-FLINT, INC. (a Delaware corp.) (US) | 1988-08-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | PTGS1 34/4885SLC7A11 3959/4885PMP22 4534/4885 |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | PTGS1 3602/4885SLC7A11 2066/4885PMP22 2589/4885 |
| US-20240000957-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | EPHA2, EPHB2, ERBB2 | PTGS1 3602/4885SLC7A11 2066/4885PMP22 2589/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | PTGS1 34/4885SLC7A11 3959/4885PMP22 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.